CD274 Antibody

What is CD274 and why are antibodies against it important in research?

CD274, also known as Programmed Death Ligand 1 (PD-L1) or B7-H1, is a type I transmembrane glycoprotein belonging to the B7 family of co-stimulatory molecules. It is encoded by a gene located on human chromosome 9p24 . CD274 serves as a ligand for CD279 (PD-1) receptor and plays a critical role in regulating T cell activation and tolerance.

These antibodies are crucial research tools because CD274 has dual functions:

• Inhibition of activated effector T cells via ligation to PD-1, leading to IL-10 secretion

• Co-stimulation of naïve T cells during early T cell priming and differentiation

Research significance includes:

• Study of immune checkpoint mechanisms in tumor microenvironments

• Investigation of immune evasion in chronic infections

• Analysis of autoimmune disease pathways

• Development and validation of immunotherapeutic approaches

What are the typical applications for CD274 antibodies in laboratory research?

CD274 antibodies have diverse applications in research settings, with validation across multiple techniques:

Most applications require optimization, and researchers should titrate antibodies in each testing system to obtain optimal results .

What tissues and cell types are recommended for validating CD274 antibody specificity?

Based on extensive validation data, researchers should consider these positive control samples:

For Western Blot validation:

• Human placenta tissue

• IFN-gamma treated A549 cells

• MDA-MB-231 cells

• U-87 MG cells

• A375 cells

• HeLa and HepG2 cells

For IHC validation:

• Human tonsillitis tissue (strong positive control)

• Human placenta tissue

• Human stomach cancer tissue

• Mouse heart tissue

For IF/ICC validation:

• HEK-293 cells

• Paraffin-embedded human placenta tissue

When validating antibody specificity, using interferon-gamma treated cells is particularly useful as CD274 expression is upregulated by this cytokine .

How should optimal dilutions be determined for CD274 antibodies across different applications?

Determining optimal antibody dilutions is critical for generating reliable data. Methodological approach:

• Start with manufacturer's recommended ranges:

  • Western Blot: 1:500-1:5000

  • IHC: 1:50-1:1200

  • IF/ICC: 1:10-1:100

• Conduct dilution series experiments:

  • Prepare at least 3-4 dilutions within recommended range

  • Include a positive control sample with known CD274 expression

  • For Western blots, load consistent protein amounts (25μg/lane recommended)

• Evaluate signal-to-noise ratio:

  • Optimal dilution shows clear specific signal with minimal background

  • Document exposure times for standardization (60s exposure has worked well in published protocols)

• Sample-dependent optimization:

  • Different cell lines may require different dilutions

  • Tumor samples often require more optimization than cell lines

  • Consider tissue-specific blocking (3% nonfat dry milk in TBST is effective)

The titration process may need to be repeated when changing sample types or experimental conditions .

What are the recommended antigen retrieval methods for IHC detection of CD274?

Effective antigen retrieval is crucial for CD274 detection in fixed tissues. The search results indicate two validated approaches:

Primary recommended method:

• TE buffer pH 9.0 (Tris-EDTA)

• Heating method: typically pressure cooker or microwave

• Time: 15-20 minutes at appropriate temperature

Alternative method:

• Citrate buffer pH 6.0

• May be less effective but suitable for certain tissue types

• Particularly useful when performing multiplex staining with antibodies requiring acidic retrieval

Optimization considerations:

• Compare both methods on your specific tissue

• Monitor protein integrity with consistent positive controls

• Consider tissue-specific requirements (e.g., placenta vs. tonsil)

• For highly fixed tissues, extended retrieval times may be necessary

Regardless of method chosen, complete cooling to room temperature before proceeding with immunostaining to prevent non-specific binding .

What storage conditions are optimal for maintaining CD274 antibody activity and stability?

Proper storage is essential for maintaining antibody performance over time. Based on the search results:

Short-term storage (up to 2 weeks):

• 4°C is acceptable for immediate use

• Avoid repeated freeze-thaw cycles during this period

Long-term storage (optimal conditions):

• -20°C is recommended by most manufacturers

• Some antibody preparations are stable at -20°C for one year after shipment

• Divide into small aliquots (no less than 20 μl) before freezing

• Never freeze at temperatures above -20°C

Storage buffer composition impacts stability:

• Most CD274 antibodies are provided in buffers containing:

  • PBS with 0.02-0.09% sodium azide

  • 50% glycerol pH 7.3 (for cryoprotection)

  • Some contain BSA (0.1%) for additional stability

Handling recommendations:

• Avoid repeated freeze-thaw cycles as this denatures the antibody

• Storage in frost-free freezers is not recommended due to temperature fluctuations

• Thaw completely before use and mix gently (avoid vortexing)

• Follow manufacturer's guidance on aliquoting requirements

How can CD274 antibodies be used to investigate the PD-1/PD-L1 signaling axis in tumor microenvironments?

Investigating the PD-1/PD-L1 signaling axis in tumor microenvironments requires sophisticated experimental approaches:

Multiplex immunohistochemistry/immunofluorescence:

• Use CD274 antibodies in combination with markers for:

  • T cell subsets (CD3, CD4, CD8)

  • Myeloid cells (CD68, CD11c)

  • Tumor markers (cytokeratins, tumor-specific antigens)

• Sequential staining protocols may be necessary when using the 29E.2A3 clone with Alexa Fluor 700 antibody conjugates

Spatial analysis:

• Quantify distances between CD274+ cells and immune infiltrates

• Correlate expression with immune exclusion zones in tumors

• Map expression relative to vasculature and hypoxic regions

Functional studies:

• Use blocking CD274 antibodies in co-culture experiments to assess:

  • T cell proliferation responses

  • Cytokine production profiles (particularly IL-10)

  • Cytotoxic activity against tumor targets

Clinical correlations:

• Analyze CD274 expression patterns in relation to:

  • Treatment response to immunotherapy

  • Patient survival outcomes

  • Metastatic potential

CD274 expression in the tumor microenvironment appears to be one of the main mechanisms by which cancer can evade the immune system via inhibiting anti-tumor T-cell immunity , making these investigations crucial for immunotherapy development.

What are the methodological approaches for quantifying CD274 protein expression levels in clinical samples?

Accurate quantification of CD274 in clinical samples requires rigorous methodological approaches:

Immunohistochemistry (IHC) quantification:

• Standardized staining protocol (1:300-1:1200 dilution range optimal)

• Digital image analysis using validated algorithms

• Scoring systems:

  • Proportion score (percentage of CD274+ cells)

  • Intensity score (0-3 scale)

  • Combined scores (H-score or Allred)

• Cell-specific analysis (tumor cells vs. immune infiltrates)

Flow cytometry quantification:

• Single-cell suspensions from fresh tissue

• Multiparameter panels including:

  • CD274 (APC or PE conjugates well-validated)

  • Lineage markers

  • Viability dye

• Quantification metrics:

  • Percentage of positive cells

  • Median fluorescence intensity (MFI)

  • Molecules of equivalent soluble fluorochrome (MESF)

Mass spectrometry-based approaches:

• Immuno-MRM (Multiple Reaction Monitoring) recommended for CPTC-CD274-1 antibody

• Targeted peptide quantification after immunoprecipitation

• Absolute quantification using isotope-labeled standards

Standardization considerations:

• Include validated positive controls (tonsillitis tissue, IFN-γ treated cell lines)

• Consistent protein loading (25μg recommended for Western blot)

• Account for heterogeneity within the sample

These approaches provide complementary data for comprehensive CD274 expression analysis in clinical specimens.

How can researchers distinguish between different glycosylated forms of CD274 in experimental systems?

CD274 undergoes significant post-translational modifications, particularly glycosylation, which affects its molecular weight and potentially its function:

Western blot analysis considerations:

• The calculated molecular weight of CD274 is 33 kDa

• Observed molecular weights vary significantly:

  • 45-56 kDa (primary band)

  • 65-70 kDa (potential heavily glycosylated form)

  • 40-50 kDa (commonly reported range)

Experimental approaches to distinguish glycoforms:

• Enzymatic deglycosylation:

  • PNGase F treatment to remove N-linked glycans

  • Comparison of migration patterns before and after treatment

  • Sequential digestion with specific glycosidases

• Gradient gel systems:

  • Use 4-15% gradient gels for optimal resolution

  • Load both treated and untreated samples

  • Include molecular weight markers spanning 25-75 kDa range

• Lectin affinity analysis:

  • Lectin blotting after protein separation

  • Lectin affinity chromatography before immunodetection

  • Combined lectin-immunoprecipitation approaches

• Mass spectrometry characterization:

  • Glycopeptide mapping after tryptic digestion

  • Site-specific glycan characterization

  • Glycoproteomic analysis of immunoprecipitated CD274

Understanding these glycoforms is critical as glycosylation may affect:

• Protein stability and half-life

• Receptor binding properties

• Immunogenicity and antibody recognition

• Functional activity in immune regulation

What are common sources of false positives/negatives in CD274 antibody-based assays and how can they be addressed?

Researchers should be aware of these common challenges and implement appropriate controls:

Sources of false positives:

• Cross-reactivity issues:

  • Verify antibody specificity with knockout/knockdown controls

  • Confirm with multiple antibody clones targeting different epitopes

  • Use species-matched negative control tissues

• Non-specific binding:

  • Optimize blocking (3% nonfat dry milk in TBST effective)

  • Validate secondary antibody specificity

  • Perform isotype control staining (mouse IgG1 for MIH2 clone)

• Detection artifacts:

  • Endogenous peroxidase activity in IHC

  • Autofluorescence in IF

  • Insufficient washing causing high background

Sources of false negatives:

• Epitope masking:

  • Test alternative antigen retrieval methods

  • Compare TE buffer pH 9.0 vs. citrate buffer pH 6.0

  • Consider extended retrieval times for heavily fixed samples

• Suboptimal antibody concentration:

  • Perform titration across recommended dilution ranges

  • Adjust incubation times and temperatures

  • Consider signal amplification systems for low-abundance targets

• Sample preparation issues:

  • Overfixation masking epitopes

  • Protein degradation during extraction

  • Inadequate deparaffinization in FFPE tissues

Validation strategies:

• Include known positive controls (tonsillitis tissue, placenta)

• Use IFN-γ treated and untreated samples in parallel

• Implement orthogonal detection methods

How can researchers troubleshoot unexpected molecular weight variations when detecting CD274 by Western blot?

CD274 exhibits significant molecular weight variations in Western blots that can complicate interpretation:

Expected weight patterns:

• Calculated molecular weight: 33 kDa

• Commonly observed bands: 45-56 kDa, 65-70 kDa

• Alternative reported weight: 40-50 kDa

Troubleshooting methodological approach:

• Sample preparation optimization:

  • Test different lysis buffers (RIPA vs. NP-40)

  • Include protease inhibitor cocktails

  • Compare fresh vs. frozen samples

  • Evaluate different protein denaturation conditions

• Post-translational modification analysis:

  • Enzymatic deglycosylation (PNGase F, EndoH)

  • Phosphatase treatment

  • Comparison across different cell activation states

  • IFN-γ treatment to upregulate expression

• Gel and transfer conditions:

  • Optimize gel percentage (8-12% recommended)

  • Adjust transfer conditions for high molecular weight proteins

  • Use protein ladders spanning 25-75 kDa range

  • Consider gradient gels for better resolution

• Antibody validation:

  • Compare different CD274 antibody clones

  • Test blocking peptide competition

  • Include knockout/knockdown controls

  • Verify with alternative detection methods

• Technical controls:

  • Load 25μg of protein per lane as standardized amount

  • Include positive control lysates (A375 cells, IFN-γ treated A549)

  • Document exposure time consistently (60s recommended)

Addressing these factors systematically can help resolve unexpected molecular weight variations.

What methodological approaches can overcome challenges in detecting low levels of CD274 expression?

Detecting low CD274 expression levels requires specialized techniques:

Signal amplification strategies:

• For IHC/IF applications:

  • Tyramide signal amplification (TSA)

  • Polymer-based detection systems

  • Extended primary antibody incubation (overnight at 4°C)

  • Higher antibody concentrations within validated range

• For Western blot enhancement:

  • Extended exposure times with high-sensitivity substrates

  • Chemiluminescent substrates with signal enhancers

  • Digital acquisition with accumulation mode

  • Concentration of protein samples before loading

• For flow cytometry:

  • Avoid blue fluorescent dyes (CF®405S) for low abundance targets

  • Use brighter fluorochromes (PE, APC) for CD274 detection

  • Implement fluorescence minus one (FMO) controls

  • Consider bead-based calibration for absolute quantification

Sample enrichment approaches:

• Immunoprecipitation before Western blot (0.5-4.0 μg antibody for 1.0-3.0 mg protein)

• Cell sorting of specific populations before analysis

• IFN-γ treatment to upregulate CD274 expression

• Isolation of membrane fractions to concentrate target protein

Technical considerations:

• Reduce background through optimized blocking and washing

• Include positive controls with known expression levels

• Consider batch effects in multi-sample studies

• Standardize image acquisition parameters

These approaches should be systematically evaluated based on your specific experimental system.

How should researchers interpret heterogeneous CD274 expression patterns in tumor tissues?

Heterogeneous CD274 expression in tumors requires sophisticated interpretation:

Pattern classification approaches:

• Spatial distribution patterns:

  • Membranous vs. cytoplasmic vs. nuclear localization

  • Tumor-infiltrating immune cell vs. tumor cell expression

  • Margin vs. core expression

  • Proximity to vascular structures

• Quantitative assessment frameworks:

  • Percentage of positive cells (fractional area)

  • Intensity scoring (0-3 scale)

  • Combined scoring systems (H-score)

  • Digital image analysis with machine learning

• Contextual interpretation:

  • Correlation with immune infiltrate markers

  • Association with hypoxic regions

  • Relationship to proliferation markers

  • Comparison with normal adjacent tissue

Biological significance of patterns:

• Constitutive upregulation of CD274 has been identified in solid tumors

• Tumor microenvironment expression represents a primary immune evasion mechanism

• IFN-γ-induced expression vs. constitutive expression may have different implications

• Membranous expression is most relevant for PD-1 interaction

Reporting recommendations:

• Document scoring methodology precisely

• Report both intensity and percentage of positive cells

• Distinguish between tumor and immune cell expression

• Include representative images of different expression patterns

These interpretation frameworks facilitate standardized analysis across laboratories and clinical studies.

What are the appropriate positive and negative controls for CD274 antibody validation across different experimental systems?

Rigorous controls are essential for CD274 antibody validation:

Positive control samples:

Negative control approaches:

• Technical negative controls:

  • Isotype control antibodies (match host species and isotype)

  • Secondary-only controls (omit primary antibody)

  • Blocking peptide competition

• Biological negative controls:

  • CD274 knockout/knockdown samples

  • Cell lines with confirmed low/absent expression

  • Tissues known to lack CD274 expression

  • Untreated paired samples (without IFN-γ induction)

Validation metrics:

• Signal-to-noise ratio measurement

• Reproducibility across different lots

• Consistency across technical replicates

• Correlation with orthogonal detection methods

Implementation of these controls significantly increases confidence in experimental findings and facilitates troubleshooting.

How can CD274 antibody data be integrated with gene expression and proteomics datasets for comprehensive analysis?

Integrating CD274 antibody data with other omics approaches provides deeper biological insights:

Integration methodologies:

• Correlation with transcriptomics:

  • Compare CD274 protein levels with mRNA expression

  • Analyze alternative splicing patterns using RNA-seq

  • Identify transcriptional regulators through promoter analysis

  • Map expression to specific cell types using single-cell RNA-seq

• Proteomics integration:

  • Combine with mass spectrometry-based proteomics

  • Targeted proteomics using Immuno-MRM approaches

  • Pathway analysis incorporating interacting proteins

  • Post-translational modification mapping

• Multi-omics frameworks:

  • Implement systematic data normalization procedures

  • Use dimensionality reduction techniques for visualization

  • Apply machine learning for pattern recognition

  • Develop integrated network models

Technical considerations:

• Account for different dynamic ranges across platforms

• Implement appropriate batch correction methods

• Address missing data systematically

• Consider temporal aspects of gene and protein expression

Biological interpretation frameworks:

• Contextual analysis of immune checkpoint pathways

• Correlation with clinical outcomes and biomarkers

• Integration with immune cell deconvolution results

• Examination of regulatory mechanisms controlling expression

Recommended databases and tools:

• TCGA and cBioPortal for cancer genomics data

• Human Protein Atlas for tissue expression patterns

• Immune Cell Atlas for cell-type specific expression

• STRING for protein-protein interaction networks